Le Lézard
Classified in: Health
Subjects: PDT, TDS

Registration now open for Spring Pharmaceutical Synchrotron XRPD Workshop


Meet us at Argonne National Laboratory, May 12-13

WEST LAFAYETTE, Ind., March 31, 2025 /PRNewswire/ -- The Spring Synchrotron X-Ray Powder Diffraction (SPS-XRPD) Workshops are a collaborative initiative led by Excelsus Structural Solutions (Switzerland), Purdue University, Argonne National Laboratory, and Improved Pharma (USA). These workshops serve as a platform for experts from the pharmaceutical industry and the Synchrotron X-Ray Powder Diffraction community to address key challenges in pharmaceutical R&D, explore the latest advancements in synchrotron XRPD, and discuss cutting-edge applications.

In 2024, the SPS-XRPD Workshop was held at the prestigious Novartis Pharma Campus in Basel, marking a significant milestone as Novartis Pharma officially joined the Organizing Committee.

To accommodate a broad international audience, the workshops alternate annually between the USA and Switzerland. Participants engage in discussions on critical topics, including phase identification and stability assessments, structural characterization, prediction and modelling, quantification of crystalline phases, even in trace amounts.  A special session covers the Pair Distribution Function method for characterizing amorphous and nano-crystalline formulations

The 2025 SPS-XRPD Workshop will introduce an exciting new theme: Pharmaceutical Crystallization and Characterization Under Non-Standard Conditions. This includes an exploration of microgravity crystallization in space, opening new frontiers in structural studies.

Join us for insightful discussions, cutting-edge research, and a unique opportunity to connect with experts shaping the future of pharmaceutical materials science.

About Improved Pharma
Improved Pharma is a research, consulting, and information company dedicated to improving pharmaceutical methods, formulations, and processes. Services include solid-state form studies, formulation design, synchrotron techniques, analytical testing, and expert consulting for the development and defense of intellectual property matters. The company was founded in 2006 by Stephen and Sarah Byrn, who also founded SSCI.

For more information about Improved Pharma's services, please contact us at 1-765-463-9951 or [email protected].

About Excelsus Structural Solutions

Excelsus Structural Solutions is a spin-off company of the Paul Scherrer Institute, which offers analytical services and scientific consultancy to the pharma and chemical industry based on synchrotron radiation. Services include ab-initio structure solution from powder diffraction data, qualitative and quantitative structural analysis at state-of-the-art Level of Detection and Quantitation, Small Angle Scattering. The company was founded by CEO Fabia Gozzo in 2012.

For more information about Excelsus' services, please contact us at +41-79-8303201 or [email protected].

About The Advanced Photon Source at Argonne National Laboratory

The Advanced Photon Source (APS) at the U.S. Department of Energy's Argonne National Laboratory provides ultra-bright, high-energy storage ring-generated x-ray beams for research in almost all scientific disciplines. These x-rays allow scientists to pursue new knowledge about the structure and function of a wide range of materials including the development of new pharmaceuticals.

More information about the Advanced Photon Source can be found here.

SOURCE Improved Pharma


These press releases may also interest you

at 08:05
Fasikl, a trailblazing neuro-AI company redefining the intersection of advanced bioelectronic medicine and artificial intelligence (AI), today announced that results from the TRANQUIL pivotal study evaluating the efficacy and safety of the FelixTM...

at 08:05
Cognito Therapeutics, a pioneering neurotechnology company developing disease-modifying therapies for neurodegenerative diseases, today announced new data from its OVERTURE feasibility trial at the AD/PDtm 2025 International Conference on Alzheimer's...

at 08:05
Today, Revvity, Inc. announced that its software and informatics division, Revvity Signals Software, will launch its Signals Onetm, a unified software platform evolved from the Company's existing research portfolio, designed to streamline data...

at 08:05
Xcellbio announced today that it had granted bluebird bio, Inc., a commercial license and entered into a supply agreement for the use of Xcellbio's proprietary cell manufacturing technology, AVATARtm, to support commercialization of LYFGENIA® gene...

at 08:05
Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, announced today the introduction of Clareon® PanOptix® Pro intraocular lens (IOL) for cataract patients in the U.S. PanOptix Pro leverages proprietary...

at 08:05
Revvity, Inc. , today announced that the U.S. Food and Drug Administration (FDA) has approved the Auto-Pure 2400 liquid handling platform with the T-SPOTtm.TB test. Initially launched outside the U.S. in 2024, this powerful combination allows...



News published on and distributed by: